Pulmonary vasculopathy in explanted lungs from patients with interstitial lung disease undergoing lung transplantation.
interstitial fibrosis
lung transplantation
primary pulmonary hypertension
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
18
11
2019
revised:
21
04
2020
accepted:
03
06
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
11
6
2021
Statut:
ppublish
Résumé
Pulmonary hypertension (PH) causes increased morbidity and mortality in patients with interstitial lung diseases (ILD). Classification schemes, while well-characterised for the vasculopathy of idiopathic PH, have been applied, unchallenged, to ILD-related PH. We evaluated pulmonary arterial histopathology in explanted human lung tissue from patients who were transplanted for advanced fibrotic ILD. Lung explants from 38 adult patients who underwent lung transplantation were included. Patients were divided into three groups: none, mild/moderate and severe PH by mean pulmonary artery pressure (mPAP) measured at pre lung transplantation right heart catheterisation (RHC). Grading of pulmonary vasculopathy according to Heath and Edwards scheme, and prelung transplantation evaluation data were compared between the groups. 38 patients with fibrotic ILDs were included, the majority (21) with idiopathic pulmonary fibrosis. Of the 38 patients, 18 had severe PH, 13 had mild/moderate PH and 7 had no PH by RHC. 16 of 38 patients had severe pulmonary arterial vasculopathy including vascular occlusion with intimal fibrosis and/or plexiform lesions. There were no correlations between mPAP and lung diffusion with the severity of pulmonary arterial pathological grade (Spearman's rho=0.14, p=0.34, rho=0.11, p=0.49, respectively). Patients with end stage ILD had severe pulmonary arterial vasculopathy in their explanted lungs irrespective of the presence and/or severity of PH as measured by RHC. These findings suggest that advanced pulmonary arterial vasculopathy is common in patients with advanced fibrotic ILD and may develop prior to the clinical detection of PH by RHC.
Sections du résumé
BACKGROUND
Pulmonary hypertension (PH) causes increased morbidity and mortality in patients with interstitial lung diseases (ILD). Classification schemes, while well-characterised for the vasculopathy of idiopathic PH, have been applied, unchallenged, to ILD-related PH. We evaluated pulmonary arterial histopathology in explanted human lung tissue from patients who were transplanted for advanced fibrotic ILD.
METHODS
Lung explants from 38 adult patients who underwent lung transplantation were included. Patients were divided into three groups: none, mild/moderate and severe PH by mean pulmonary artery pressure (mPAP) measured at pre lung transplantation right heart catheterisation (RHC). Grading of pulmonary vasculopathy according to Heath and Edwards scheme, and prelung transplantation evaluation data were compared between the groups.
RESULTS
38 patients with fibrotic ILDs were included, the majority (21) with idiopathic pulmonary fibrosis. Of the 38 patients, 18 had severe PH, 13 had mild/moderate PH and 7 had no PH by RHC. 16 of 38 patients had severe pulmonary arterial vasculopathy including vascular occlusion with intimal fibrosis and/or plexiform lesions. There were no correlations between mPAP and lung diffusion with the severity of pulmonary arterial pathological grade (Spearman's rho=0.14, p=0.34, rho=0.11, p=0.49, respectively).
CONCLUSIONS
Patients with end stage ILD had severe pulmonary arterial vasculopathy in their explanted lungs irrespective of the presence and/or severity of PH as measured by RHC. These findings suggest that advanced pulmonary arterial vasculopathy is common in patients with advanced fibrotic ILD and may develop prior to the clinical detection of PH by RHC.
Identifiants
pubmed: 32661103
pii: 7/1/e000532
doi: 10.1136/bmjresp-2019-000532
pmc: PMC7359183
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Am J Respir Crit Care Med. 2002 Aug 1;166(3):314-22
pubmed: 12153963
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 1;308(3):L229-52
pubmed: 25416383
Am J Respir Cell Mol Biol. 2011 Jul;45(1):1-15
pubmed: 21057104
Chest. 2006 Mar;129(3):746-52
pubmed: 16537877
J Heart Lung Transplant. 2012 Apr;31(4):373-80
pubmed: 22226804
Eur Respir J. 2007 Oct;30(4):715-21
pubmed: 17626111
Am J Respir Crit Care Med. 2005 Jul 15;172(2):189-94
pubmed: 15831842
Circulation. 1958 Oct;18(4 Part 1):533-47
pubmed: 13573570
Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9
pubmed: 21474646
Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81
pubmed: 17901413
N Engl J Med. 2010 Aug 12;363(7):620-8
pubmed: 20484178
Lancet Respir Med. 2014 Apr;2(4):293-300
pubmed: 24717626
Circulation. 2010 Jun 29;121(25):2747-54
pubmed: 20547927
J Heart Lung Transplant. 2013 Mar;32(3):347-54
pubmed: 23265910
Chest. 2017 Jan;151(1):204-214
pubmed: 27554299
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Am J Pathol. 2011 Jul;179(1):167-79
pubmed: 21703400
Am J Respir Crit Care Med. 2012 Aug 1;186(3):261-72
pubmed: 22679007
Am J Respir Crit Care Med. 2010 Feb 1;181(3):270-8
pubmed: 19875684
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16
pubmed: 24355635
Chest. 2010 Jun;137(6 Suppl):39S-51S
pubmed: 20522579
Am J Respir Crit Care Med. 2016 Mar 1;193(5):484-5
pubmed: 26930432
Eur Respir J. 2008 Sep;32(3):619-28
pubmed: 18448495
Circulation. 1989 Nov;80(5):1198-206
pubmed: 2805258
Am J Pathol. 1999 Aug;155(2):411-9
pubmed: 10433934
Cardiovasc Ther. 2012 Apr;30(2):93-9
pubmed: 21884013
Eur Respir J. 2013 Dec;42(6):1622-32
pubmed: 23682110
Chest. 2018 Jan;153(1):217-223
pubmed: 28629920
Ann Intern Med. 2013 May 7;158(9):641-9
pubmed: 23648946
Am J Respir Crit Care Med. 2014 Jul 15;190(2):208-17
pubmed: 24937643
COPD. 2012 Jun;9(3):268-75
pubmed: 22360383
Clin Chest Med. 2013 Dec;34(4):639-50
pubmed: 24267295
Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1013-32
pubmed: 19748998
Histopathology. 2017 May;70(6):896-905
pubmed: 27992963
Eur Respir J. 2013 Oct;42(4):982-92
pubmed: 23429918
Semin Respir Crit Care Med. 2013 Oct;34(5):551-9
pubmed: 24037624
Can Respir J. 2017;2017:1430350
pubmed: 28286407
Eur Respir J. 2013 Jun;41(6):1324-30
pubmed: 23728404
Eur Respir Rev. 2013 Sep 1;22(129):292-301
pubmed: 23997057
Eur Respir J. 2008 Apr;31(4):759-64
pubmed: 18094009
Chest. 2012 Nov;142(5):1087-1088
pubmed: 23131930